Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.642
Neutral
RSI(14)
44.216
Neutral
STOCH(KDJ)(9,3,3)
27.460
Sell
ATR(14)
1.891
High Vlolatility
CCI(14)
-139.691
Sell
Williams %R
78.600
Sell
TRIX(12,20)
0.161
Sell
StochRSI(14)
18.911
Oversold
Search
Alkermes Plc
ALKSAdd to Watchlist
48.990USD
-1.040-2.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.22BMarket Cap
52.69P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.08%
5 Days
-7.37%
1 Month
-6.50%
6 Months
+44.56%
Year to Date
+75.09%
1 Year
+84.94%
Key Figures
49.630Open
49.830High
1.62MVolume
52.69P/E TTM
54.53P/E Dynamic
--Dividend TTM
0.97%Turnover Ratio
50.030Prev. Close
48.520Low
59.71MTurnover
22.36P/E Static
4.54P/B
0.00%Div Yield TTM
4.82%ROA
40.79052wk High
0.68Volume Ratio
367.07MNet Profit
167.54MShares
0.9298EPS TTM
0.31Beta
9.36%ROE
25.16552wk Low
2.62%Amplitude
75.67%Gross Margin
8.22BMarket Cap
-3.73Reward/Risk
2.23%Risk Rate
TradingKey Stock Score of Alkermes Plc
Currency: USD Updated: 2026-07-31Key Insights
Alkermes Plc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 25 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.10.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alkermes Plc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Alkermes Plc Highlights
StrengthsRisks
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Overvalued
The company’s latest PE is 52.69, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 182.39M shares, decreasing 6.17% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.08.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
55.098
Target Price
+13.98%
Upside Space
Alkermes Plc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
19
analysts
Buy
Current Rating
55.098
Target Price
+13.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Alkermes Plc
ALKS
19
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
50.118
Sell
MA10
51.360
Sell
MA20
52.204
Sell
MA50
47.726
Buy
MA100
40.323
Buy
MA200
35.499
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alkermes Plc Info
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Ticker SymbolALKS
CompanyAlkermes Plc
CEOPops (Richard F)
Websitehttps://www.alkermes.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Alkermes Plc (ALKS)?
The current price of Alkermes Plc (ALKS) is 48.99.
What is the symbol of Alkermes Plc?
The ticker symbol of Alkermes Plc is ALKS.
What is the 52-week high of Alkermes Plc?
The 52-week high of Alkermes Plc is 40.79.
What is the 52-week low of Alkermes Plc?
The 52-week low of Alkermes Plc is 25.16.
What is the market capitalization of Alkermes Plc?
The market capitalization of Alkermes Plc is 8.21B.
Is Alkermes Plc (ALKS) currently rated as Buy, Hold, or Sell?
According to analysts, Alkermes Plc (ALKS) has an overall rating of Buy, with a price target of 55.10.
What is the Earnings Per Share (EPS TTM) of Alkermes Plc (ALKS)?
The Earnings Per Share (EPS TTM) of Alkermes Plc (ALKS) is 1.47.